Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Coeptis Therapeutics Holdings (COEP) Cost of Revenue (2021 - 2025)

Coeptis Therapeutics Holdings (COEP) has 4 years of Cost of Revenue data on record, last reported at $45155.0 in Q3 2025.

  • For Q3 2025, Cost of Revenue changed N/A year-over-year to $45155.0; the TTM value through Sep 2025 reached $135468.0, up 1165.75%, while the annual FY2021 figure was $2918.0, N/A changed from the prior year.
  • Cost of Revenue reached $45155.0 in Q3 2025 per COEP's latest filing, up from -$16187.0 in the prior quarter.
  • Across five years, Cost of Revenue topped out at $141518.0 in Q1 2021 and bottomed at -$84052.0 in Q4 2022.
  • Average Cost of Revenue over 4 years is $27957.5, with a median of $9526.0 recorded in 2022.
  • The widest YoY moves for Cost of Revenue: up 84.88% in 2023, down 92.6% in 2023.
  • A 4-year view of Cost of Revenue shows it stood at $141518.0 in 2021, then plummeted by 159.39% to -$84052.0 in 2022, then soared by 84.88% to -$12711.0 in 2023, then skyrocketed by 455.24% to $45155.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cost of Revenue were $45155.0 in Q3 2025, -$16187.0 in Q2 2025, and $106500.0 in Q1 2025.